Saltar al contenido principal

ETHNOS_APP

Inicio • Búsqueda • Revistas • Lista 0

Understanding the Challenges of Adjuvant Treatment Measurement and Reporting in Breast Cancer

Cancer Treatment Measuring and Reporting

Datos Bibliográficos

ID9099296
AutoresNina A Bickell (0000-0003-1102-8677, Icahn School of Medicine at Mount Sinai, autor de correspondencia), Ann Scheck Mcalearney (0000-0001-9107-5419, Ecole polytechnique fédérale de Lausanne), Jill Wellner (Veterans Health Administration), Kezhen Fei (0000-0002-1545-9688, autor de correspondencia), Rebeca Franco (0000-0002-2974-6506, autor de correspondencia)
Año2013
Volumen51
Número6
Páginase35-e40
Fecha de publicación2013-06-01
Peer ReviewedSí
Open AccessNo
TipoARTICLE
RevistaMedical Care (JOURNAL)
Identificadores de la revistaISSN: 0025-7079 • E-ISSN: 1537-1948
EditorialOvid Technologies (Wolters Kluwer Health) (PUBLISHER)
DOI10.1097/mlr.0b013e3182422f7b
PMID22214980
PMCIDPMC3521861
OpenAlexW1993093757
IdiomaEN
Citas recibidas1
Referencias citadas7

BACKGROUND: Healthcare accrediting organizations and insurers increasingly require reporting of clinical data, and cancer treatment is one area of enhanced scrutiny. OBJECTIVES: To compare rates of received versus reported adjuvant breast cancer treatments, and to assess barriers to measuring and reporting treatments to the tumor registry (TR) of a high-volume medical center with both hospital-based and community-based oncologists. RESEARCH DESIGN: We calculated rates of received treatments using data collected using chart abstraction (N=115) and compared these with rates of reported treatments from the TR (N=535). We conducted 31 indepth interviews with clinical and administrative informants. Asking about perceptions of the TR, current reporting methods, and reporting barriers. Interviews were recorded, transcribed, and analyzed using deductive and inductive methods. RESULTS: : Rates of reported versus received treatments were radiation therapy after breast-conserving surgery 22% versus 84% (P < 0.0001); chemotherapy for stage 2 or 3: 17% versus 79% (P < 0.0001); hormonal therapy for stage 2 or 3: 1% versus 91% (P < 0.0001). Comparing community-based versus hospital-based oncologists' rates reported to the TR, we found the following differences: radiation therapy post-breast conserving surgery 12% versus 32% (< 0.0001); chemotherapy 8% versus 29% (< 0.0001); and hormonal therapy 0% versus 3% (0.09). We found 4 key barriers to measuring and reporting poor understanding about the TR, limited information technology capabilities, poor communication, and mistrust. CONCLUSIONS: : Efforts to improve cancer care quality by improved treatment reporting must overcome key barriers, especially those involving information exchange and mistrust. Communications between the TR and oncology practices must improve to facilitate better treatment measurement and reporting

Adjuvant · Breast cancer · Cancer · Medical physics · MEDLINE · Breast Cancer Treatment Studies · Chemistry · Economic and Financial Impacts of Cancer · Global Cancer Incidence and Screening · Internal Medicine · Medicine · Oncology

  • Women With Breast Cancer in the Veterans Health Administration

    Sarah Colonna, Sarah V Colonna et al.•Medical Care•2015

  • Profiling Providers on Use of Adjuvant Chemotherapy by Combining Cancer Registry and Medical Record Data

    Hui Zheng, Recai M Yucel et al.•Medical Care•2006

  • Qualitative Analysis as a Public Event

    Open Access•Mark A Constas•American Educational Research…•1992

Obras citantes distintas1
Citas por año0,09
Intervalo de citas2015 - 2015 (1)
Velocidad de citaciónhistorical
Altamente citadoNo
Tipos de citaNeutras: 1
Ethnos_APP • Proyecto Open Source • Licencia MIT • Frontend v2.0.0 • Privacidad y Cookies • Documentación de la API: api.ethnos.app/docs • Código de la API: GitHub • DOI: 10.5281/zenodo.17049435 • Código del Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae